GSK and Oxford Collaborate to Pave the Way for Life-Saving Cancer Vaccines

A second research collaboration between SK and the University of Oxford allows analysis of cancer prevention through vaccine therapy.

The GSK-Oxford immuno-anticipation program will conduct translational research by studying precancer science to better understand human cancer evolution which creates potential opportunities for new vaccines.

Early research follows GSK’s commitment of up to £50m ($62.3m) across three years.

Oxford University’s expertise in precancer science will be deployed through the new program to sequence and identify neoantigens which developers can potentially use to block cancer progression.

GSK boss logical official Tony Wood expressed: We are delighted to strengthen our bond with Oxford University while bringing deep scientific insights from both GSK and Oxford academic experts.

Research into precancer science combined with GSK’s expertise in studying immune responses will allow us to create essential information for disease prevention in at-risk populations.